Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 8/20 | 0.39 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769325 | 1.00 | MAPK1 (0.44) | MAPK1KDM4EHPGDPARP1PLA2G2D | |
| SCHEMBL10450919 | 0.84 | PARP1 (0.39) | KDM4EHPGDPARP1 | |
| SCHEMBL2188295 | 0.81 | PARP1 (0.39) | KDM4EHPGDPARP1PIM3 | |
| SCHEMBL170674 | 0.80 | KDM4E (0.47) | KDM4EHPGDPARP1 | |
| SCHEMBL4813379 | 0.80 | PARP1 (0.38) | KDM4EHPGDPARP1PIM3 | |
| SCHEMBL29453826 | 0.80 | KDM4E (0.47) | KDM4EHPGDPARP1 | |
| Phosphine SCHEMBL4726258 | 0.78 | KDM4E (0.46) | KDM4EHPGDPARP1 | |
| SCHEMBL3840407 | 0.78 | KDM4E (0.46) | KDM4EHPGDPARP1 | |
| SCHEMBL9172345 | 0.78 | KDM4E (0.46) | KDM4EHPGDPARP1 | |
| SCHEMBL1698316 | 0.78 | PARP1 (0.56) | PARP1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117615622-B | Method for preparing solar cell with assistance of (trifluoroacetyl) benzotriazole | 南开大学 | 2025-03-07 | — | — | CN | claimed |
| CN-118562565-A | Stable semiconductor chip cleaning liquid and preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | claimed |
| CN-117615622-A | Method for preparing solar cell with assistance of (trifluoroacetyl) benzotriazole | 南开大学 | 2024-02-27 | — | — | CN | claimed |
| WO-2024024935-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE HAVING ANTINEOPLASTIC EFFECT | 第一三共株式会社 | 2024-02-01 | — | — | WO | claimed |
| EP-4286393-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2023-12-06 | — | — | EP | claimed |
| CN-116867795-A | Novel method for producing antibody-immunostimulant conjugate | 第一三共株式会社 | 2023-10-10 | — | — | CN | claimed |
| WO-2022163846-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | 第一三共株式会社 | 2022-08-04 | — | — | WO | claimed |
| EP-2985286-B1 | MIDBODY OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-10-11 | — | — | EP | claimed |
| US-9359366-B2 | Intermediate of Ticagrelor and preparation method therefor, and preparation method for Ticagrelor | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-07 | — | — | US | claimed |
| US-20160052928-A1 | INTERMEDIATE OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-02-25 | — | — | US | claimed |
| EP-2985286-A1 | MIDBODY OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2016-02-17 | — | — | EP | claimed |
| CN-122029306-A | Method for producing conductive particles and conductive powder | 日本化学工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-120202515-A | Conductive particle, method for producing same, conductive material, and connection structure using same | 日本化学工业株式会社 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025079669-A1 | METHOD FOR PRODUCING CONDUCTIVE PARTICLES, AND CONDUCTIVE POWDER | 日本化学工業株式会社 | 2025-04-17 | — | — | WO | disclosed |
| CN-119768874-A | Conductive particle, method for producing same, and conductive material | 日本化学工业株式会社 | 2025-04-04 | — | — | CN | disclosed |
| US-6685995-B1 | LOW VOLTAGE, WIDE TEMPERATURE RANGE DRIVING; HIGH SPEED RESPONSE | CHISSO CORPORATION (JP) | 2004-02-03 | — | — | US | disclosed |
| US-20030119751-A1 | Selective neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY | 2003-06-26 | — | — | US | disclosed |
| WO-2003000198-A2 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1053996-A1 | ESTER COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY DEVICES | CHISSO CORPORATION (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | PAICS, COASY, CDS2 | MAPK1 3524/4885KDM4E 4464/4885HPGD 1226/4885 |
| US-20160052928-A1 | INTERMEDIATE OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | POR, CYP2C19, TKFC | MAPK1 1403/4885KDM4E 3537/4885HPGD 217/4885 |
| US-20030119751-A1 | Selective neuronal nitric oxide synthase inhibitors | NOS1, NOS3, NOS2 | MAPK1 861/4885KDM4E 2422/4885HPGD 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.